3D artist Jigar Patel (@jigpx) makes mesmerizing computer graphic animations. He created a series of brilliant clips called “Logo Factory”, and it's quite hard to stop looking at them
TikTok: https://t.co/23Dvr1CsRj
Instagram: https://t.co/GrGuT4bQey
1/ The intersection of Healthcare x Fintech = a meaty zone in which to build. But where to start? What makes for a good play? What learnings from general fintech apply? Some thoughts from Team @a16z Healthcare x Fintech: https://t.co/LMIo0Ug0TR
He would have been successful no matter where he chose to practice either in academics or the community (please don't take this to mean that one should be preferred). My larger message is that we should be focusing on finding good people, not just looking at school name brands.
The three I just read:
7 types of angel investors: https://t.co/YGa81SN2cY
VC economics:
https://t.co/EGDmPvzEqd
Questions VCs will ask you:
https://t.co/DZhublK0xu
The @StanfordMedRes Residency Research Symposium is an annual highlight @StanfordDeptMed. Congratulations to all the residents on their phenomenal research accomplishments! 👏🏻👏🏻
@chrissyfarr These situations exist because PBMs take a percentage cut of rebate and also protect rebate flows so they can competitively market to health plans. Unfortunately very few articles on pharma pricing fully explain this dynamic.
@chrissyfarr Important caveat to this framing: the 7k comes back as rebate *after* PBM/plan initially paid out 10k list price. Hurts patients with co-insurance based on list. Also hurts PR for pharma industry because public only sees list price and not the effective $3k net price.
I spent the past decade of my career in sales strategy at @Slack, @Intercom @Zenefits and saw so many opportunities to apply the same tactics to #recruiting
But I don’t see most companies embracing this yet and it can give them an edge 🧵